Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis

Leukemia

Volumn 28, Issue 7, 2014, Pages 1486-1493

  Tabarroki, A ^a   Lindner, D J ^a   Visconte, V ^a   Zhang, L ^b   Rogers, H J ^c   Parker, Y ^a   Duong, H K ^a   Lichtin, A ^a   Kalaycio, M E ^a   Sekeres, M A ^a   Mountantonakis, S E ^d   Heresi, G A ^e   Tiu, R V ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e Respiratory Institute   (United States)

Author keywords

myelofibrosis; pulmonary hypertension; ruxolitinib

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DANAZOL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; NITRIC OXIDE; PREDNISONE; RUXOLITINIB; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; VON WILLEBRAND FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MALE; MOUSE; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; THROMBOCYTE TRANSFUSION;

AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; FERRITINS; HUMANS; HYPERTENSION, PULMONARY; JANUS KINASES; MALE; MICE, KNOCKOUT; MIDDLE AGED; NITRIC OXIDE; PRIMARY MYELOFIBROSIS; PYRAZOLES;

EID: 84904070596     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.5     Document Type: Article

References (70)

1. Tabarroki A, Tiu RV. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs 2012 21 1141-1154.
2. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis the Mayo clinic experience. Mayo Clin Proc 2012 87 25-33.
3. Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008 22 646-649.
4. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 26 113 2895-2901.
5. Guilpain P, Montani D, Damaj G, Achouh L, Lefrere F, Le Pavec J et al. Pulmonary hypertension associated with myeloproliferative disorders a retrospective study of ten cases. Respiration 2008 76 295-302.
6. Krug S, Seyfarth HJ, Hagendorff A, Wirtz H. Inhaled iloprost for hepatopulmonary syndrome improvement of hypoxemia. Eur J Gastroenterol Hepatol 2007 19 1140-1143.
7. Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007 74 287-292.
8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997 336 111-117.
9. Hassell KL. Pulmonary hypertension, tricuspid regurgitant velocity screening, and the nitric oxide pathway. Hematology Am Soc Hematol Educ Program 2011 2011 419-426.
10. Hayes Jr. D. Idiopathic pulmonary arterial hypertension misdiagnosed as asthma. J Asthma 2007 44 19-22.
11. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003 361 1533-1544.
12. Simonneau G. [A new clinical classification of pulmonary hypertension]. Bull Acad Natl Med 2009 193 1897-1909.
13. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999 60 130-135.
14. Rostagno C, Prisco D, Abbate R, Poggesi L. Pulmonary hypertension associated with long-standing thrombocytosis. Chest 1991 99 1303-1305.
15. De Klippel N, Dehou MF, Bourgain C, Schots R, De Keyser J, Ebinger G. Progressive paraparesis due to thoracic extramedullary hematopoiesis in myelofibrosis. Case report. J Neurosurg 1993 79 125-127.
16. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010 85 192-199.
17. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D et al. Primary pulmonary hypertension improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997 30 343-349.
18. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension a randomised placebo-controlled study. Lancet 2001 358 1119-1123.
19. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000 95 19-29.
20. Vainchenker W, Favale F. Myelofibrosis JAK2 inhibitors and erythropoiesis. Leukemia 2013 27 1219-1223.
21. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005 32 1650-1653.
22. Ananthakrishnan R, Hallam K, Li Q, Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascul Pharmacol 2005 43 353-356.
23. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013 368 161-170.
24. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007 293 548-554.
25. Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu HL et al. U.S. Food and Drug Administration approval ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012 18 3212-3217.
26. Verstovsek S. Ruxolitinib an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med 2013 125 128-135.
27. Keohane C, Mesa R, Harrison C. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms. Am Soc Clin Oncol Educ Book 2013 2013 301-305.
28. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ et al. Progressive burden of myelofibrosis in untreated patients assessment of patientreported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 2013 16 1-6.
29. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54(1 Suppl) S55-S66.
30. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society Inc., and the Pulmonary Hypertension Association. Circulation 2009 119 2250-2294.
31. Kiatchoosakun S, Wongvipaporn C, Nanagara R, Hoit BD. Right ventricular systolic pressure assessed by echocardiography a predictive factor of mortality in patients with scleroderma. Clin Cardiol 2011 34 488-493.
32. Sarkar R, Gelabert HA, Mohiuddin KR, Thakor DK, Santibanez-Gallerani AS. Effect of cigarette smoke on endothelial regeneration in vivo and nitric oxide levels. J Surg Res 1999 82 43-47.
33. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase an in vitro demonstration in human coronary artery endothelial cells. Circulation 2003 107 2342-2347.
34. Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W et al. Dose response of almonds on coronary heart disease risk factors blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide a randomized, controlled, crossover trial. Circulation 2002 106 1327-1332.
35. Choi JW, Pai SH, Kim SK, Ito M, Park CS, Cha YN. Iron deficiency anemia increases nitric oxide production in healthy adolescents. Ann Hematol 2002 81 1-6.
36. Odemis E, Koca C, Karadag A, Catal F, Aydin M, Turkay S et al. Nitric oxide affects serum ferritin levels in children with iron deficiency. Pediatr Hematol Oncol 2007 24 189-194.
37. Sudarma V, Sukmaniah S, Siregar P. Effect of dark chocolate on nitric oxide serum levels and blood pressure in prehypertension subjects. Acta Med Indones 2011 43 224-228.
38. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001 70 270-279.
39. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007 3 567-577.
40. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002 99 11375-11380.
41. Qi Y, Jamindar TM, Dawson G. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J Neurochem 1995 64 2458-2464.
42. Rhodes CJ, Wharton J, Wilkins MR. Pulmonary hypertension biomarkers. Handb Exp Pharmacol 2013 218 77-103.
43. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A et al. Pulmonary hypertension in patients with sickle cell disease a longitudinal study. Br J Haematol 2006 134 109-115.
44. Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006 296 310-318.
45. Van Beers EJ, Nur E, Schaefer-Prokop CM, Mac Gillavry MR, van Esser JW, Brandjes DP et al. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am J Hematol 2008 83 850-854.
46. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007 92 738-743.
47. Njaman W, Iesaki T, Iwama Y, Takasaki Y, Daida H. Serum uric acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Int Heart J 2007 48 523-532.
48. Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR et al. Vardenafil treatment for patients with pulmonary arterial hypertension a multicentre, open-label study. Heart 2009 95 1531-1536.
49. Ulrich S, Fischler M, Speich R. Update on therapies for pulmonary hypertension. Swiss Med Wkly 2007 137 73-82.
50. Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008 295 C1183-C1190.
51. Lopes AA, Barreto AC, Maeda NY, Cicero C, Soares RP, Bydlowski SP et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. Braz J Med Biol Res 2011 44 1269-1275.
52. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006 98 525-529.
53. Zharikov SI, Swenson ER, Lanaspa M, Block ER, Patel JM, Johnson RJ. Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses 2010 74 1069-1074.
54. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003 17 2115-2117.
55. Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H et al. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis a pilot study. Rheumatol Int 2011 31 263-267.
56. Collados MT, Sandoval J, Lopez S, Masso FA, Paez A, Borbolla JR et al. Characterization of von Willebrand factor in primary pulmonary hypertension. Heart Vessels 1999 14 246-252.
57. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000 96 1342-1347.
58. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 2004 381 761-767.
59. Ichinose F, Roberts Jr. JD, Zapol WM. Inhaled nitric oxide a selective pulmonary vasodilator current uses and therapeutic potential. Circulation 2004 109 3106-3111.
60. Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm 1999 57 25-48.
61. Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005 42 133-136.
62. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998 158 917-923.
63. Chan ED, Riches DW. IFN-gamma\+LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001 280 C441-C450.
64. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. Regulation of cytokineinducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha. J Biol Chem 1996 271 1111-1117.
65. Takaki H, Minoda Y, Koga K, Takaesu G, Yoshimura A, Kobayashi T. TGF-beta1 suppresses IFN-gamma-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Genes Cells 2006 11 871-882.
66. Wang C, Yang F, Xu Z, Shi D, Chen D, Dai J et al. Intravenous release of NO from lipidic microbubbles accelerates deep vein thrombosis resolution in a rat model. Thromb Res 2013 131 e31-e38.
67. Fang C, Stavrou E, Schmaier AA, Grobe N, Morris M, Chen A et al. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/-mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 2013 121 3023-3032.
68. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012 186 790-796.
69. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib survival advantage in comparison to matched historical controls. Blood 2012 120 1202-1209.
70. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis a comprehensive cytokine profiling study. J Clin Oncol 2011 29 1356-1363.